6H-Dibenzooxocin | 262-91-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 6H-Dibenzooxocin
• 英文别名: (11Z)-6H-benzo[c][1]benzoxocine
• CAS: 262-91-9
• 化学式: C₁₅H₁₂O
• 分子量: 208.26
• InChiKey: YHUWYWBRZKGELG-KTKRTIGZSA-N

物化性质

• 沸点：
  354.4±37.0 °C(Predicted)
• 密度：
  1.120±0.06 g/cm3(Predicted)
• 熔点：
  81-82 °C

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  6H-Dibenzooxocin 在 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 反应 24.0h， 以90%的产率得到11,12-Epoxy-11,12-dihydro-6H-dibenzooxocin
  参考文献：
  名称：

  Synthesis of 6H-Dibenzo[b,f]-oxocin

  摘要：

  DOI：

  10.1055/s-1981-29379
• 作为产物：
  描述：

  2-溴甲基苄基三苯基溴化膦 在 sodium methylate 作用下， 以 甲醇 、 水 、 丙酮 、 甲苯 为溶剂， 反应 0.08h， 生成 6H-Dibenzooxocin
  参考文献：
  名称：

  Synthesis of 6H-Dibenzo[b,f]-oxocin

  摘要：

  DOI：

  10.1055/s-1981-29379

文献信息

• Novel synthesis of oxocine derivatives by Wittig olefination and intramolecular Heck reaction via 8-endo trig cyclization
  作者：K.C. Majumdar、B. Chattopadhyay、B. Sinha

  DOI：10.1016/j.tetlet.2007.12.096

  日期：2008.2

  A concise and efficient method for the preparation of oxocine derivatives is described via sequential Wittig and intramolecular Heck reactions. The method is highly regioselective and affords high yields of the products.

  通过连续的维蒂希（Wittig）和分子内Heck反应描述了一种简单而有效的制备氧代辛衍生物的方法。该方法是高度区域选择性的，并提供高产率的产物。
• Novel sequences encoding hepatitis C virus glycoproteins
  申请人：Dumonceaux Julie

  公开号：US20050266400A1

  公开（公告）日：2005-12-01

  The present invention concerns a modified nucleic acid molecule comprising a nucleotide sequence coding for a full length hepatitis C virus (HCV) glycoprotein selected from the group consisting of E1 glycoprotein and E1/E2 glycoprotein heterodimer, this molecule having at least one nucleotide alteration, wherein, due to this alteration, at least one RNA splice site selected from the group consisting of RNA splice acceptor and RNA splice donor sites is eliminated from the coding sequence. The invention is also directed to methods for expressing on the surface of a cell and a pseudovirion an HCV glycoprotein, wherein the majority of the glycoprotein is full length. The invention further provides a cell and a pseudovirion expressing such glycoprotein. The invention still further provides a method for determining whether an agent inhibits HCV fusion with and entry into a target cell. The invention also provides an agent that inhibits HCV fusion with and entry into a target cell. The invention further provides methods for treating a subject afflicted with an HCV-associated disorder, for preventing an HCV infection in a subject, and for inhibiting in a subject the onset of an HCV-associated disorder.

  本发明涉及一种修饰的核酸分子，该分子包含编码全长丙型肝炎病毒（HCV）糖蛋白的核苷酸序列，该糖蛋白选自由E1糖蛋白和E1/E2糖蛋白杂二聚体组成的组，该分子具有至少一个核苷酸改变，其中，由于该改变，从编码序列中消除了至少一个选自由RNA剪接接受位点和RNA剪接供体位点组成的组的RNA剪接位点。本发明还涉及在细胞和假病毒表面表达 HCV 糖蛋白的方法，其中大部分糖蛋白是全长的。本发明进一步提供了表达这种糖蛋白的细胞和假病毒。本发明还进一步提供了一种确定药剂是否能抑制 HCV 与靶细胞融合并进入靶细胞的方法。本发明还提供了一种抑制 HCV 与靶细胞融合和进入靶细胞的药剂。本发明进一步提供了治疗受 HCV 相关疾病困扰的受试者、预防受试者感染 HCV 以及抑制受试者患上 HCV 相关疾病的方法。
• Palladium(0)-Catalyzed Intramolecular Heck Reaction: A Resourceful Route for the Synthesis of Naphthoxepine and Naphthoxocine Derivatives
  作者：K. Majumdar、Inul Ansary、Biswajit Sinha、Buddhadeb Chattopadhyay

  DOI：10.1055/s-0029-1216984

  日期：2009.11

  The synthesis of oxocines and oxepines is difficult. Two efficient protocols have been developed for the construction of naphthoxepine and naphthoxocine derivatives by sequential Wittig olefination and intramolecular Heck reaction.
• BEGASSE B.; CORRE M. LE, SYNTHESIS, 1981, NO 3, 197
  作者：BEGASSE B.、 CORRE M. LE

  DOI：——

  日期：——
• L-SIGN polymorphisms and methods involving use of same
  申请人：Gardner P. Jason

  公开号：US20060292151A1

  公开（公告）日：2006-12-28

  This invention concerns methods for determining whether an agent preferentially binds to at least one allelic variant of L-SIGN. The invention is also directed to agents that preferentially bind to at least one allelic variant of L-SIGN. The invention also provides methods and agents for treating and preventing disorders associated with infection by pathogens, including hepatitis C virus, that bind to particular L-SIGN allelic variants. The invention further provides methods for predicting the resistance or susceptibility of a subject to pathogen infection.